IL165370A0 - Therapeutic agent for overactive bladder - Google Patents

Therapeutic agent for overactive bladder

Info

Publication number: IL165370A0
Authority: IL; Israel
Prior art keywords: therapeutic agent; overactive bladder; overactive; bladder; therapeutic
Prior art date: 2002-06-07

Application number

IL16537003A

Other languages

English (en)

Original Assignee

Astellas Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-06-07

Filing date

2003-06-05

Publication date

2006-01-15

2003-06-05 Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc

2006-01-15 Publication of IL165370A0 publication Critical patent/IL165370A0/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IL16537003A 2002-06-07 2003-06-05 Therapeutic agent for overactive bladder IL165370A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2002166408		2002-06-07
PCT/JP2003/007149 WO2003103659A1 (ja)	2002-06-07	2003-06-05	過活動膀胱治療剤

Publications (1)

Publication Number	Publication Date
IL165370A0 true IL165370A0 (en)	2006-01-15

Family

ID=29727628

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL16537003A IL165370A0 (en)	2002-06-07	2003-06-05	Therapeutic agent for overactive bladder

Country Status (16)

Country	Link
US (2)	US20060035923A1 (ja)
EP (1)	EP1552825A4 (ja)
JP (1)	JP4466370B2 (ja)
KR (1)	KR20050008795A (ja)
CN (1)	CN100355419C (ja)
AR (1)	AR040248A1 (ja)
AU (1)	AU2003242166A1 (ja)
BR (1)	BR0311414A (ja)
CA (1)	CA2487899A1 (ja)
IL (1)	IL165370A0 (ja)
MX (1)	MXPA04012070A (ja)
NO (1)	NO20050060L (ja)
PL (1)	PL372560A1 (ja)
RU (1)	RU2004135563A (ja)
TW (1)	TW200408387A (ja)
WO (1)	WO2003103659A1 (ja)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7442387B2 (en) *	2003-03-06	2008-10-28	Astellas Pharma Inc.	Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
US20050175689A1 (en) *	2003-10-27	2005-08-11	Yamanouchi Pharmaceutical Co., Ltd.	Coated fine particles containing drug for intrabuccally fast disintegrating tablet
US8197846B2 (en) *	2003-11-10	2012-06-12	Astellas Pharma Inc.	Sustained release pharmaceutical composition
ZA200608614B (en) *	2004-03-25	2008-06-25	Astellas Pharma Inc	Composition for solid pharmaceutical preparation of solifenacin or salt thereof
PL2156824T3 (pl) *	2004-03-25	2013-03-29	Astellas Pharma Inc	Kompozycja solifenacyny lub jej soli do zastosowania w formulacji stałej
EP1832288B1 (en) *	2004-12-27	2012-06-20	Astellas Pharma Inc.	Stable granular pharmaceutical composition of solifenacin or its salt
ES2387571T3 (es) *	2004-12-27	2012-09-26	Astellas Pharma Inc.	Composición farmacéutica granulada estable de solifenacina o de su sal
US20090131469A1 (en) *	2005-02-25	2009-05-21	Astellas Pharma Inc.	Pharmaceutical agent comprising solifenacin
US7815939B2 (en) *	2005-07-20	2010-10-19	Astellas Pharma Inc.	Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms
KR20100040294A (ko) *	2007-07-20	2010-04-19	아스텔라스세이야쿠 가부시키가이샤	전립선 비대에 수반되는 하부 요로 증상의 개선용 의약 조성물
PT2216021E (pt)	2007-11-02	2012-11-06	Astellas Pharma Inc	Composição farmacêutica para tratar uma bexiga hiperactiva
CA2709727A1 (en) *	2007-12-21	2009-07-02	Astellas Pharma Inc.	Pharmaceutical composition for improving lower urinary tract symptoms
EP2181707A1 (en) *	2008-11-04	2010-05-05	Astellas Ireland Co., Ltd.	Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent
WO2010090172A1 (ja) *	2009-02-04	2010-08-12	アステラス製薬株式会社	経口投与用医薬組成物
US9119878B2 (en) *	2010-07-08	2015-09-01	Wellesley Pharmaceuticals, Llc	Extended-release formulation for reducing the frequency of urination and method of use thereof
KR102027912B1 (ko) *	2011-02-15	2019-10-02	지엘팜텍주식회사	경구투여용 탐술로신 또는 이의 약제학적으로 허용되는 염을 포함하는 서방성 삼중정제
WO2013142197A1 (en) *	2012-03-19	2013-09-26	Wellesley Pharmaceuticals, Llc	Extended-release formulation for reducing the frequency of urination and method of use thereof
CN102743757A (zh) *	2012-07-09	2012-10-24	张家华	治疗膀胱流出道梗阻所致膀胱活动过度的药物
US10596127B2 (en)	2013-03-14	2020-03-24	Wellesley Pharmaceuticals, Llc	Composition for reducing the frequency of urination, method of making and use thereof
CN106265667B (zh) *	2015-05-18	2019-01-25	中国科学院生物物理研究所	一种氯喹的用途
CN106562968B (zh) *	2015-10-13	2019-08-13	南京华威医药科技集团有限公司	包含盐酸坦洛辛和琥珀酸索利那新的药物组合物
KR101879133B1 (ko) *	2017-07-11	2018-07-17	(주)동구바이오제약	비뇨기 질환 예방 또는 치료용 제제 및 이의 제조방법
MX2022013103A (es) *	2020-04-27	2022-11-30	Zim Laboratories Ltd	Nueva composicion farmaceutica multiparticulada de tamsulosina y solifenacina.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5391825A (en) *	1980-02-08	1995-02-21	Yamanouchi Pharmaceutical Co., Ltd.	Sulfamoyl substituted phenethylamine intermediates
NO2005012I1 (no) *	1994-12-28	2005-06-06	Debio Rech Pharma Sa	Triptorelin og farmasoytisk akseptable salter derav
US6319920B1 (en) *	1998-02-27	2001-11-20	Syntex (U.S.A.) Llc	2-arylethyl-(piperidin-4-ylmethyl)amine derivatives
TW536402B (en) *	1998-06-26	2003-06-11	Yamanouchi Pharma Co Ltd	Pharmaceutical composition for the therapy of voiding dysfunction
TR200102583T2 (tr) *	1999-08-09	2002-07-22	Yamanouchi Pharmaceutical Co., Ltd.	Alt idrar yolları semptomlarının tedavisine yönelik farmasötik bileşim.
IL141235A (en) *	2000-02-09	2012-04-30	Novartis Int Pharm Ltd	Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
AU2004227945B2 (en) *	2003-04-04	2006-10-26	Dynogen Pharmaceuticals, Inc.	Method of treating lower urinary tract disorders

2003
- 2003-06-05 MX MXPA04012070A patent/MXPA04012070A/es active IP Right Grant
- 2003-06-05 IL IL16537003A patent/IL165370A0/xx unknown
- 2003-06-05 CN CNB038131498A patent/CN100355419C/zh not_active Expired - Fee Related
- 2003-06-05 WO PCT/JP2003/007149 patent/WO2003103659A1/ja not_active Ceased
- 2003-06-05 JP JP2004510778A patent/JP4466370B2/ja not_active Expired - Lifetime
- 2003-06-05 KR KR10-2004-7019807A patent/KR20050008795A/ko not_active Ceased
- 2003-06-05 RU RU2004135563/15A patent/RU2004135563A/ru not_active Application Discontinuation
- 2003-06-05 BR BR0311414-7A patent/BR0311414A/pt not_active IP Right Cessation
- 2003-06-05 AU AU2003242166A patent/AU2003242166A1/en not_active Abandoned
- 2003-06-05 CA CA002487899A patent/CA2487899A1/en not_active Abandoned
- 2003-06-05 PL PL03372560A patent/PL372560A1/xx unknown
- 2003-06-05 EP EP03730850A patent/EP1552825A4/en not_active Withdrawn
- 2003-06-05 US US10/517,137 patent/US20060035923A1/en not_active Abandoned
- 2003-06-06 TW TW092115435A patent/TW200408387A/zh unknown
- 2003-06-06 AR ARP030102019A patent/AR040248A1/es not_active Application Discontinuation
2005
- 2005-01-06 NO NO20050060A patent/NO20050060L/no not_active Application Discontinuation
2006
- 2006-12-22 US US11/643,762 patent/US20070270459A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN1658859A (zh)	2005-08-24
US20070270459A1 (en)	2007-11-22
KR20050008795A (ko)	2005-01-21
CA2487899A1 (en)	2003-12-18
PL372560A1 (en)	2005-07-25
EP1552825A1 (en)	2005-07-13
EP1552825A4 (en)	2009-11-25
US20060035923A1 (en)	2006-02-16
CN100355419C (zh)	2007-12-19
MXPA04012070A (es)	2005-03-07
BR0311414A (pt)	2005-03-15
TW200408387A (en)	2004-06-01
AR040248A1 (es)	2005-03-23
NO20050060L (no)	2005-03-04
WO2003103659A1 (ja)	2003-12-18
AU2003242166A1 (en)	2003-12-22
JPWO2003103659A1 (ja)	2005-10-06
JP4466370B2 (ja)	2010-05-26
RU2004135563A (ru)	2005-06-10

Publication	Publication Date	Title
IL165370A0 (en)	2006-01-15	Therapeutic agent for overactive bladder
GB0206876D0 (en)	2002-05-01	Therapeutic agents
GB0229931D0 (en)	2003-01-29	Therapeutic agents
GB0209991D0 (en)	2002-06-12	Therapeutic agents
GB0209997D0 (en)	2002-06-12	Therapeutic agents
GB0209995D0 (en)	2002-06-12	Therapeutic agents
GB0210127D0 (en)	2002-06-12	Therapeutic agents
GB0230087D0 (en)	2003-01-29	Therapeutic agents
GB0223349D0 (en)	2002-11-13	Therapeutic agents
GB0303910D0 (en)	2003-03-26	Therapeutic agents
GB0210124D0 (en)	2002-06-12	Therapeutic agents
GB0230088D0 (en)	2003-01-29	Therapeutic agents
GB0310401D0 (en)	2003-06-11	Therapeutic agent
GB0323378D0 (en)	2003-11-05	Therapeutic agent
GB0301350D0 (en)	2003-02-19	Therapeutic agents
GB0218876D0 (en)	2002-09-25	Therapeutic agents
PL397022A1 (pl)	2012-03-26	Środek leczniczy
GB0225501D0 (en)	2002-12-11	Therapeutic agents
GB0208394D0 (en)	2002-05-22	Therapeutic agents
GB0217068D0 (en)	2002-08-28	Therapeutic agents
GB0226462D0 (en)	2002-12-18	Therapeutic agents
GB0307333D0 (en)	2003-05-07	Therapeutic agent
GB0225399D0 (en)	2002-12-11	Therapeutic agents
GB0207509D0 (en)	2002-05-08	Therapeutic agent
GB0307335D0 (en)	2003-05-07	Therapeutic agent

Legal Events

Date	Code	Title	Description
2005-11-20	HC	Change of name of proprietor(s)